Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that OR-101, a selective JAK3/TEK inhibitor, was associated with dose-dependent improvements in hair growth in humanized mice with alopecia areata, suggesting its potential as a treatment option.

In this study, researchers found that ex vivo and in vivo administration of the TYK2 inhibitor BMS-986202 prevented immune privilege collapse and promoted hair regrowth in models of alopecia areata, suggesting this approach may offer a new therapeutic avenue deserving of clinical investigation.

This article discusses baricitinib, a JAK1 and JAK2 inhibitor, as an approved and promising treatment for alopecia areata but reports no new clinical results.

This review suggests that novel treatment developments targeting the pathomechanics of alopecia areata, such as JAK inhibitors, show promise, although optimal treatment strategies are still under investigation.

In this study, a mouse model of scarring alopecia demonstrated significantly reduced CD200R expression in affected skin, which may contribute to immune attacks on hair follicles.

This source highlights that the incidence of alopecia areata is increasing among children, and while corticosteroids and Janus kinase inhibitors show potential effectiveness and safety, they remain unapproved by the FDA for pediatric use.

This pilot study suggests that lovastatin may counteract stress-induced MICA expression in hair follicles and enhance MICA shedding, potentially offering a complementary approach for alopecia areata treatment.

This study found that autologous γdTregs displayed significant protective effects on alopecia areata-affected human scalp hair follicles in both ex vivo and in vivo settings, suggesting potential for future cell-based therapy.

This study found that ILC1-like cells can induce alopecia areata in healthy human hair follicles, challenging the traditional belief that the disease is primarily driven by CD8+ T cells.

This study found that innate lymphoid cells-type 1 can induce alopecia areata characteristics in human hair follicles both ex vivo and in vivo, challenging the view of it as solely an autoimmune disease driven by CD8+ T cells.

This study provides evidence that ILC1-like cells can induce alopecia areata in previously healthy human hair follicles, challenging the view that it is solely an autoantigen-dependent autoimmune disease.

This study found that ILC1-like cells can induce alopecia areata symptoms in both ex vivo human hair follicles and in vivo mouse models, challenging the view that alopecia areata is solely CD8+ T cell-driven.

This review summarizes existing literature on COVID-19-associated alopecia, finding that androgenic alopecia may increase COVID-19 risk, while telogen effluvium often follows infection.

This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.

This study found that the proprietary aptamer TAGX-0003 significantly inhibited IFNγ-induced effects in pre-clinical human models of alopecia areata, promoting hair regrowth and potentially preventing disease relapse.

This study found that ILC1-like cells can induce alopecia areata in healthy human hair follicles, suggesting that these cells might be a therapeutic target in AA management.

This review outlines the proposed theories behind the development of alopecia areata, emphasizing the autoimmune process involving lost immune privilege in hair follicles, and stresses the need to pinpoint specific pathogenic mechanisms for potential treatments.

This review suggests that excessive facial photoprotection could play a role in frontal fibrosing alopecia through a disturbance in immunological balance via the aryl hydrocarbon receptor-kynurenine pathway.

This study suggests that in alopecia areata, innate lymphoid cells type 1 may contribute to the disease’s pathogenesis by inducing hair follicle changes similarly to CD8+ T cells.

This study found that epidermal growth factor receptor and mitogen activated protein kinase inhibitors down-regulate PD-L1 expression in human hair follicles, which may contribute to sterile folliculitis in treated patients.

This study suggests that miR-486 may protect against alopecia areata by maintaining hair follicle immune privilege and modulating expression of immune-related genes.

This study found that electrical epilation in organ-cultured human scalp skin perturbs hair follicles by causing inflammation, impairing melanin production, and possibly inhibiting post-epilation hair re-growth.

This study found that miR-486 and miR-451 levels were reduced in alopecia areata-affected skin, and delivering their mimics to mice mitigated symptoms by reducing inflammation and immune activity.

This review discusses the pathogenesis and new treatments for alopecia areata, highlighting the role of the hair follicle's immune and hormone systems and potential therapies like JAK inhibitors and immunomodulators.

This article reviews alopecia areata treatment strategies, noting that while various therapies exist, none are curative or preventive and many lack randomized, controlled trials.

This study observed that Langerhans cells and melanocytes migrated to hair follicle sites during human embryogenesis, suggesting that Langerhans cells acquire immunoregulatory properties there.

The conference highlighted new diagnostic tools, the role of genetics in hair loss, and emerging treatments.

This study found that nerve growth factor signaling in organ-cultured human hair follicles inhibits hair growth by inducing apoptosis-driven hair follicle regression.

This study reports that stress-related neurohormones and factors, such as CRH and SP, can inhibit hair growth and alter immune functions in murine and human hair follicles.

The document concludes that understanding hair biology is key to treating hair disorders, with gene therapy showing potential as a future treatment.